Pfizer Inc. (NYSE:PFE) Shares Sold by Marshall Wace LLP

Marshall Wace LLP trimmed its position in shares of Pfizer Inc. (NYSE:PFE) by 47.3% in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 7,759,490 shares of the biopharmaceutical company’s stock after selling 6,970,717 shares during the period. Marshall Wace LLP’s holdings in Pfizer were worth $205,859,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Nordea Investment Management AB increased its position in Pfizer by 36.1% in the 4th quarter. Nordea Investment Management AB now owns 4,071,700 shares of the biopharmaceutical company’s stock valued at $108,002,000 after acquiring an additional 1,080,822 shares during the period. Parsons Capital Management Inc. RI increased its holdings in shares of Pfizer by 118.7% during the fourth quarter. Parsons Capital Management Inc. RI now owns 294,764 shares of the biopharmaceutical company’s stock valued at $7,820,000 after purchasing an additional 159,984 shares during the period. Copley Financial Group Inc. acquired a new position in shares of Pfizer during the third quarter valued at $577,000. Mcdonald Partners LLC raised its stake in shares of Pfizer by 9.9% during the fourth quarter. Mcdonald Partners LLC now owns 110,296 shares of the biopharmaceutical company’s stock valued at $2,926,000 after purchasing an additional 9,963 shares in the last quarter. Finally, Merit Financial Group LLC lifted its holdings in Pfizer by 60.8% in the fourth quarter. Merit Financial Group LLC now owns 127,967 shares of the biopharmaceutical company’s stock worth $3,395,000 after purchasing an additional 48,397 shares during the period. Institutional investors own 68.36% of the company’s stock.

Analysts Set New Price Targets

A number of research firms have commented on PFE. Hsbc Global Res upgraded shares of Pfizer to a “strong-buy” rating in a research report on Monday, March 10th. UBS Group lowered their price objective on shares of Pfizer from $28.00 to $24.00 and set a “neutral” rating on the stock in a research note on Tuesday, April 8th. Guggenheim reaffirmed a “buy” rating on shares of Pfizer in a research note on Tuesday, March 18th. Citigroup reissued a “neutral” rating on shares of Pfizer in a research note on Thursday, March 27th. Finally, Truist Financial decreased their target price on Pfizer from $36.00 to $32.00 and set a “buy” rating for the company in a research note on Wednesday, December 18th. One investment analyst has rated the stock with a sell rating, eight have given a hold rating, six have given a buy rating and three have assigned a strong buy rating to the company. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $31.07.

Insider Buying and Selling at Pfizer

In related news, Director Ronald E. Blaylock purchased 19,457 shares of Pfizer stock in a transaction dated Thursday, February 13th. The stock was acquired at an average cost of $25.65 per share, with a total value of $499,072.05. Following the completion of the transaction, the director now directly owns 27,707 shares of the company’s stock, valued at $710,684.55. This trade represents a 235.84 % increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Company insiders own 0.06% of the company’s stock.

Pfizer Stock Up 1.5 %

PFE stock opened at $22.45 on Wednesday. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.00 and a quick ratio of 0.73. The firm has a market capitalization of $127.30 billion, a P/E ratio of 15.92, a P/E/G ratio of 0.64 and a beta of 0.67. Pfizer Inc. has a 52-week low of $20.92 and a 52-week high of $31.54. The company’s 50 day simple moving average is $25.09 and its 200-day simple moving average is $26.31.

Pfizer (NYSE:PFE) last released its earnings results on Tuesday, February 4th. The biopharmaceutical company reported $0.63 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.48 by $0.15. Pfizer had a return on equity of 19.47% and a net margin of 12.62%. The company had revenue of $17.76 billion during the quarter, compared to analyst estimates of $17.26 billion. During the same quarter in the prior year, the company earned $0.10 earnings per share. The company’s revenue for the quarter was up 24.7% on a year-over-year basis. As a group, equities research analysts anticipate that Pfizer Inc. will post 2.95 EPS for the current year.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.